Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

149 49,465

Net cash provided by operating

activities 282,777 274,321

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of property and

equipment (55,689) (70,887)

Acquisition of intangible assets (25,575) (99,152)

Investment in third party (6,242) -

Proceeds from sale of investment

in third party - 12,291

Sales and maturities of

available-for-sale investments 7,596 28,212

Purchases of available-for-sale

investments - (71,398)

Net cash used for investing

activities (79,910) (200,934)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from exercises of

common stock options 37,185 74,375

Windfall tax benefits from

stock-based compensation 4,592 9,934

Acquisition of treasury stock (24) (128)

Payments on and retirements of

long-term debt (216,093) (2,902)

Net cash (used for) provided

by financing activities (174,340) 81,279

EFFECT OF EXCHANGE RATE CHANGES ON

CASH AND CASH EQUIVALENTS (601) 10,804

NET INCREASE IN CASH AND CASH

EQUIVALENTS 27,926 165,470

CASH AND CASH EQUIVALENTS, BEGINNING

OF PERIOD 818,669 496,512

CASH AND CASH EQUIVALENTS, END OF

PERIOD
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... -- Research and Markets  has announced ... Report 2014" report to their offering. ... Palmitic Acid Industry Report 2014 is a professional and ... palmitic acid industry. The report provides a ... and industry chain structure. The palmitic acid market analysis ...
(Date:11/26/2014)... 21, 2014 (PRWEB) November 26, 2014 ... communications network, today announced the organization has won a ... Club Awards. Digitas Health LifeBrands was honored with a ... other PHCG agencies received eight Awards of Excellence. ... aspects of pharmaceutical advertising and promotion. The Awards provide ...
(Date:11/26/2014)... The announced sales of three healthcare units ... to expand in non-healthcare areas, says Kalorama Information. Siemens ... firm says that  Siemens is the third largest company ... the IVD market , with 5.5 billion in IVD ... would likely affect IVD market shares.  ...
(Date:11/26/2014)... PMG Research, Inc. announced today the ... network of sites that provide clinical research services to pharmaceutical ... lives through its partnerships with large physician practices and integrated ... locations in the Southeastern United States and spans over 60 ... board will be held by: Dr. Robert Holmes, MD, ...
Breaking Biology Technology:Global Palmitic Acid Industry Report 2014 2Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3
... ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... 27 PDL BioPharma, Inc. (PDL, ... it has entered into separate privately negotiated exchange agreements under ... the Company,s outstanding 2.00% Convertible Senior Notes due February 15, ... holders of the 2012 Notes will receive $92.0 million in ...
Cached Biology Technology:Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 2Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 3Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 4Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 5Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 6Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 7Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 8The New deCODE Map of the Human Genome 2The New deCODE Map of the Human Genome 3The New deCODE Map of the Human Genome 4The New deCODE Map of the Human Genome 5The New deCODE Map of the Human Genome 6The New deCODE Map of the Human Genome 7The New deCODE Map of the Human Genome 8The New deCODE Map of the Human Genome 9PDL BioPharma Announces Exchange to Retire 2.00% Convertible Senior Notes Due February 15, 2012 2PDL BioPharma Announces Exchange to Retire 2.00% Convertible Senior Notes Due February 15, 2012 3
(Date:11/21/2014)... Calif. , Nov. 20, 2014   Atmel® ... leader in microcontroller (MCU) and touch technology solutions, today ... temperature sensors with the widest V cc ... higher temperature accuracy and faster I 2 C bus ... and serial EEPROM memory making them ideal for consumer, ...
(Date:11/15/2014)... YORK , Nov. 13, 2014  While we may ... technology Doctor McCoy used in "Star Trek" to gain instant ... tools designed to work with smartphones and tablets for monitoring ... of the healthcare world. This may seem a tad Orwellian ... ready to adopt some of these technological opportunities into their ...
(Date:11/7/2014)... 2014  In conjunction with the Glendale ... Community Foundation of the Verdugos has announced the " ... a $250,000 initiative to keep the Verdugo Regional Crime Lab ... six months of existence, the Lab has processed more than ... law enforcement. "Because our number one priority is ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... With only two weeks to go and almost a ... 2013 have reached their final stages. This year,s conference ... Simons will deliver the opening keynote lecture and explain ... cells work. In further keynote lectures, Hans Clevers will ...
... 9, 2013 Cytos Biotechnology Ltd (SIX:CYTN) today ... CYT003, a first-in-class immune modulator in clinical development as a ... data published in the March issue of The Journal ... at the European Respiratory Society Annual Congress in ...
... 2013 Disease-causing bacteria stink literally and the ... the basis for a faster and simpler new way to ... here today at the 246th National Meeting & Exposition of ... The new test produces results in 24 hours, compared ...
Cached Biology News:All set for The EMBO Meeting 2013 2Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 2Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 3Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 4Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 5New 'artificial nose' device can speed diagnosis of sepsis 2
EML1 (K-16)...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
Bovine Pulmonary Artery Endothelial Cells (BPAEC) (>500,000 cells)...
Biology Products: